Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 2,065 -3.20%
12 Jun 4:01 p.m.
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

Website BSE NSE
  • Market Cap ₹ 21,574 Cr.
  • Current Price ₹ 2,065
  • High / Low ₹ 2,664 / 1,345
  • Stock P/E 57.8
  • Book Value ₹ 173
  • Dividend Yield 0.42 %
  • ROCE 29.6 %
  • ROE 22.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 19.7% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 30.0%

Cons

  • Stock is trading at 11.9 times its book value
  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
181 159 241 273 195 262 241 319 216 310 244 430
116 121 129 144 123 143 135 185 135 174 146 239
Operating Profit 65 38 112 129 72 119 106 134 81 137 98 190
OPM % 36% 24% 46% 47% 37% 45% 44% 42% 38% 44% 40% 44%
8 6 9 12 7 8 8 11 10 10 15 9
Interest 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 14 13 14 14 13 13 14 14 13 13 13 15
Profit before tax 58 30 106 126 65 113 100 131 78 133 99 185
Tax % 26% 26% 26% 26% 25% 25% 26% 26% 25% 26% 25% 23%
43 22 79 94 48 84 75 97 58 99 74 142
EPS in Rs 45.32 2.14 7.56 8.94 4.63 8.08 7.13 9.29 5.57 9.43 7.08 13.57
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
340 436 512 617 713 853 1,017 1,200
195 256 308 289 439 509 585 694
Operating Profit 145 180 205 328 274 344 432 506
OPM % 43% 41% 40% 53% 38% 40% 42% 42%
18 17 31 14 23 35 34 44
Interest 1 1 1 1 6 5 3 1
Depreciation 18 19 21 28 50 54 54 54
Profit before tax 144 178 213 313 241 320 409 496
Tax % 30% 33% 21% 25% 26% 26% 26% 25%
100 118 169 235 179 238 305 373
EPS in Rs 105.66 124.48 177.65 247.44 187.76 22.76 29.13 35.65
Dividend Payout % 0% 21% 22% 0% 3% 30% 30% 30%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 19%
TTM: 18%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: 29%
TTM: 27%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 44%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 21%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 10 10 10 10 10 10 10 10
Reserves 585 673 761 990 1,098 1,282 1,515 1,802
22 9 52 89 62 32 10 3
69 72 118 94 144 191 164 219
Total Liabilities 685 763 941 1,183 1,313 1,515 1,699 2,034
189 230 240 546 573 593 575 795
CWIP 3 19 141 18 74 173 211 50
Investments 151 229 199 142 74 138 244 335
343 285 361 477 592 611 668 854
Total Assets 685 763 941 1,183 1,313 1,515 1,699 2,034

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
79 155 167 207 246 265 245
-42 -114 -195 -112 -158 -155 -160
-37 -43 31 -100 -85 -99 -99
Net Cash Flow 0 -1 3 -4 3 12 -14

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 236 133 131 105 119 117 125 159
Inventory Days 381 310 312 503 434 430 331 286
Days Payable 210 112 201 152 185 190 150 135
Cash Conversion Cycle 407 331 242 456 368 357 306 310
Working Capital Days 275 186 160 196 179 163 169 290
ROCE % 27% 25% 32% 21% 26% 28% 30%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08%
7.30% 7.00% 6.49% 7.11% 8.10% 8.33% 9.35%
8.12% 8.40% 8.41% 10.35% 9.82% 9.65% 9.16%
40.50% 40.52% 41.03% 38.46% 38.02% 37.93% 37.41%
No. of Shareholders 1,00,92787,48683,29680,73784,29882,00481,219

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls